Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary
Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.
How this was made
The 30-second read
Why it matters
The earnings beat and sizable license milestone are likely to trigger a short‑term rally.
Market read
First report of Nurix's Q3 earnings with a major licensing boost, offering a fresh trading catalyst.
What to watch
Increased R&D spend and discontinued programs could pressure margins.
Background
Nurix Therapeutics filed its Q3 2026 10‑Q, showing a dramatic earnings swing due to a Roche partnership.
Ticker impact
Nurix Therapeutics reported Q3 2026 revenue of $673.1M and EPS of $4.73, driven by $653.2M Roche license revenue.
upward pressure as investors price in the large license milestone
The surprise swing to $549.8M net income and high EPS signals a material earnings beat.
Market effects
Boosts biotech licensing sentiment and may lift peers with similar collaborations.
U.S. biotech sector gains from strong partnership news.
Highlights Roche's licensing activity, relevant to pharma investors worldwide.
Counterpoint
License revenue may be non-recurring; future growth could be uneven.
Key entities
- companyNurix Therapeutics
Biotech firm reporting Q3 2026 results.
- partnerRoche
Provided $653.2M license revenue.
